Publication: Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection
Issued Date
2018-03-05
Resource Type
ISSN
17534666
17534658
17534658
Other identifier(s)
2-s2.0-85054729619
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Advances in Respiratory Disease. Vol.12, (2018)
Suggested Citation
Phunsup Wongsurakiat, Sirapat Tulatamakit Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection. Therapeutic Advances in Respiratory Disease. Vol.12, (2018). doi:10.1177/1753466618760134 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46834
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection
Author(s)
Other Contributor(s)
Abstract
© The Author(s), 2018. Background: We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB). Methods: Patients with VAP who received appropriate antibiotics for 7 days, temperature ⩽ 37.8°C, without shock, and CPIS ⩽ 6 were allocated to the PCT group or conventional group according to the treating physicians’ decisions. In the PCT group, antibiotics were stopped if the PCT level on day 8 < 0.5 ng/ml. In the conventional group, antibiotics were stopped according to physicians’ discretion. Results: There were 24 patients in the PCT group and 26 patients in the conventional group. NF-GNB were responsible for VAP in 79.2% of the PCT group and 65.4% of the conventional group. PCT group had a greater number of antibiotic-free days alive during the 28 days after VAP onset than the conventional group (14.6 ± 5.4 days versus 5.9 ± 5.7 days, respectively; p <.001). In the multivariate, propensity score-adjusted analysis, the PCT group [coefficient = −9.1 (–12.2 to −6); p <.001] and extrapulmonary infections [coefficient = 6.4 (3.3–9.5); p <.001] were independent predictors of total antibiotic exposure days. There was no relapse in both groups. Meanwhile, 12.5% of the PCT group and 26.9% of the conventional group subsequently developed recurrent VAP compatible with superinfections. Conclusions: CPIS and a spot serum PCT level appeared effective and safe to guide discontinuation of antibiotic treatment in patients with VAP caused by NF-GNB. Trial registration: TCTR20160726002.